fluoxetine
Adjunctive therapy • Brands: PROZAC
Last reviewed: 2026-02-01
General information
- Class: Adjunctive therapy
- Common US brands: PROZAC
- Therapeutic drug monitoring not routinely recommended.
- Last reviewed: 2026-02-01
Dosing & forms
- Forms/strengths: —
- Frequency: —
- Food: —
- Typical range: —
Mechanism (brief)
Selective serotonin reuptake inhibitor (SSRI).
Metabolism & Half‑life
- Metabolism: CYP2D6 (inhibitor)
- Half‑life: —
Therapeutic Drug Monitoring (TDM)
Recommended: No
Monitoring highlights
- —
Sources
- PROZAC (fluoxetine) prescribing information — DailyMed (2024)
- APA Clinical Practice Guideline for the Treatment of Depression — American Psychiatric Association (2023)
- CANMAT 2024 Clinical Guidelines for Major Depressive Disorder — Canadian Journal of Psychiatry (2024)
- Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder — The Lancet (2018)